EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold
Executive Summary
Approval of the first pegfilgrastim biosimilars in the EU would mark the start of a period of accelerated sales declines for Amgen's Neulasta but the outlook for the blockbuster bio-originator is not necessarily bleak.
You may also be interested in...
Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
Buoyed by the market share held by biosimilars of the short-acting neutropenia drug Neupogen, Coherus hopes its Udenyca price, contracts and services will give its biosimilar a significant share of the market for the longer-acting Neulasta.
Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
Buoyed by the market share held by biosimilars of the short-acting neutropenia drug Neupogen, Coherus hopes its Udenyca price, contracts and services will give its biosimilar a significant share of the market for the longer-acting Neulasta.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.